Torniai Mariangela, Agostinelli Veronica, Cantini Luca, Liguori Carolina, Morgese Francesca, Rinaldi Silvia, Scortichini Laura, Berardi Rossana
UOC Oncologia, Ospedale A. Murri, 63900 Fermo, Italy.
Clinica Oncologica, Università Politecnica delle Marche, AOU Ospedali Riuniti di Ancona, 60126 Ancona, Italy.
Explor Target Antitumor Ther. 2022;3(3):321-336. doi: 10.37349/etat.2022.00085. Epub 2022 Jun 10.
During the coronavirus disease 2019 (COVID-19) pandemic two needs have overlapped: on one hand continuing to provide the best care for patients with lung cancer and preventing the spread of the virus between patients and healthcare professionals on the other hand. Due to the pandemic's unpredictable duration, physicians had to evaluate the risk/benefit ratio of anti-cancer therapeutic strategy to do the best for their patients and to protect patients themselves, as well as healthcare workers.
Systematic literature research was performed with the aim to assess the available guidelines for the management of lung cancer patients during the COVID-19 pandemic. Thirteen potentially relevant articles were selected and recommendations have been divided into three main categories: dos, don'ts and don't knows.
All guidelines and recommendations highlighted the relevance of being able to delay, if possible and based on risk stratification, and curative interventions. The selected recommendations should be considered adaptable and flexible because they might be contextualized on the basis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and the availability of diagnostic-therapeutic resources.
It remains of fundamental importance to discuss each diagnostic and therapeutic decision with the patient taking into account risks and benefits that might vary from case to case.
在2019年冠状病毒病（COVID-19）大流行期间，两种需求相互重叠：一方面要继续为肺癌患者提供最佳护理，另一方面要防止病毒在患者与医护人员之间传播。由于大流行持续时间不可预测，医生必须评估抗癌治疗策略的风险/收益比，以便为患者提供最佳治疗并保护患者自身以及医护人员。
进行系统的文献研究，旨在评估COVID-19大流行期间肺癌患者管理的现有指南。选择了13篇潜在相关文章，并将建议分为三大类：应做之事、不应做之事和未知之事。
所有指南和建议都强调了在可能的情况下并基于风险分层推迟根治性干预措施的相关性。所选建议应被视为具有适应性和灵活性，因为它们可能会根据严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染率以及诊断治疗资源的可用性进行调整。
与患者讨论每个诊断和治疗决策，同时考虑到因病例而异的风险和益处，仍然至关重要。
